These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1693514)

  • 61. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.
    Addo MM; Yu XG; Rosenberg ES; Walker BD; Altfeld M
    DNA Cell Biol; 2002 Sep; 21(9):671-8. PubMed ID: 12396610
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.
    Musey L; Ding Y; Elizaga M; Ha R; Celum C; McElrath MJ
    J Immunol; 2003 Jul; 171(2):1094-101. PubMed ID: 12847284
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Borrow P; Lewicki H; Wei X; Horwitz MS; Peffer N; Meyers H; Nelson JA; Gairin JE; Hahn BH; Oldstone MB; Shaw GM
    Nat Med; 1997 Feb; 3(2):205-11. PubMed ID: 9018240
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins.
    Yang OO; Church J; Kitchen CM; Kilpatrick R; Ali A; Geng Y; Killian MS; Sabado RL; Ng H; Suen J; Bryson Y; Jamieson BD; Krogstad P
    J Virol; 2005 Dec; 79(24):15368-75. PubMed ID: 16306608
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes.
    Du Y; Zhang TH; Dai L; Zheng X; Gorin AM; Oishi J; Wu TT; Yoshizawa JM; Li X; Yang OO; Martinez-Maza O; Detels R; Sun R
    mBio; 2017 Nov; 8(6):. PubMed ID: 29184023
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.
    Harrer T; Harrer E; Kalams SA; Barbosa P; Trocha A; Johnson RP; Elbeik T; Feinberg MB; Buchbinder SP; Walker BD
    J Immunol; 1996 Apr; 156(7):2616-23. PubMed ID: 8786327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.
    Gadhamsetty S; Coorens T; de Boer RJ
    J Virol; 2016 Aug; 90(16):7066-7083. PubMed ID: 27226367
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients.
    Fukada K; Tomiyama H; Wasi C; Matsuda T; Kusagawa S; Sato H; Oka S; Takebe Y; Takiguchi M
    AIDS; 2002 Mar; 16(5):701-11. PubMed ID: 11964526
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.
    Murakoshi H; Kuse N; Akahoshi T; Zhang Y; Chikata T; Borghan MA; Gatanaga H; Oka S; Sakai K; Takiguchi M
    J Virol; 2019 Jan; 93(1):. PubMed ID: 30333175
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.
    Barouch DH; Craiu A; Santra S; Egan MA; Schmitz JE; Kuroda MJ; Fu TM; Nam JH; Wyatt LS; Lifton MA; Krivulka GR; Nickerson CE; Lord CI; Moss B; Lewis MG; Hirsch VM; Shiver JW; Letvin NL
    J Virol; 2001 Mar; 75(5):2462-7. PubMed ID: 11160750
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
    Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
    Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus.
    Klenerman P; Meier UC; Phillips RE; McMichael AJ
    Eur J Immunol; 1995 Jul; 25(7):1927-31. PubMed ID: 7542596
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env.
    Ray SC; Lubaki N; Dhruva BR; Siliciano RF; Bollinger RC
    AIDS Res Hum Retroviruses; 1998 Jan; 14(1):3-13. PubMed ID: 9453246
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets.
    McKinney DM; Lewinsohn DA; Riddell SR; Greenberg PD; Mosier DE
    J Immunol; 1999 Jul; 163(2):861-7. PubMed ID: 10395680
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection.
    Jin X; Wills M; Sissons JG; Carmichael A
    Eur J Immunol; 1998 Nov; 28(11):3564-76. PubMed ID: 9842899
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of artificial vaccines against HIV using defined epitopes.
    Berzofsky JA
    FASEB J; 1991 Jul; 5(10):2412-8. PubMed ID: 1712327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.